Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE